Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739609 · ClinicalTrials.gov registry record · Phase 1
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00739609 is a Phase 1 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 17 participants.
The verdict
NCT00739609, a Phase 1 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors.
Interventions
- DRUG 1-methyl-D-tryptophan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00739609
The ClinicalTrials.gov registry entry for NCT00739609 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 1-methyl-D-tryptophan is the first listed.
NCT00739609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00739609 about?
NCT00739609 is a clinical study titled "IDO Inhibitor Study for Relapsed or Refractory Solid Tumors". This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors.
What is the current status of trial NCT00739609?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00739609?
The interventions under investigation include: 1-methyl-D-tryptophan (DRUG).
Who is sponsoring clinical trial NCT00739609?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.